Venter, J. Craig
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Samoan Submission Machines
Samoan Submission Machines: Grappling with Representations of Samoan Identity in Professional Wrestling Theo Plothe1 Savannah State University [email protected] Amongst the myriad of characters to step foot in the squared circle, perhaps no ethnic group has been as celebrated or marginalized as the Samoans who have made their names in professional wrestling. The discussion of Samoan identity in the context of sport has examined Maori identity and masculinity in New Zealand, among other topics, but there has yet to be work which considers Samoans within professional wrestling. This research investigates Samoan identity through a content analysis of televised wrestling matches. This research identifies six primary stereotypes under which Samoan identity is portrayed. These portrayals of Samoan characters, I argue, flatten the representation of this ethnic group within wrestling and culture at large. Keywords: Samoans, identity, representation, gimmicks Introduction Among the myriad of characters to step foot in the squared circle, perhaps no ethnic group has been as celebrated or marginalized as the Samoans who have made their names in professional wrestling. This research investigates the identity of Samoans within professional wrestling, and the different ways they are constructed and presented to audiences. “Gimmicks,” characters portrayed by a wrestler “resulting in the sum of fictional elements, attire and wrestling ability” (Oliva and Calleja 3) utilized by Samoans have run the gamut from the wild uncivilized savage, to the sumo (both in villainous Japanese and comically absurd iterations), to the ultra-cool mogul who wears silk shirts and fancy shoes. Their ability to cut promos, an important facet of the modern gimmick allowing wrestlers to address their opponents and storylines, varies widely as well, but all lie within their Samoan identity. -
Download Issue
Cell Circuitry || Science Teaches English || The Chicken Genome Is Hot || Magnets in Medicine SEPTEMBER 2002 www.hhmi.org/bulletin Leading Doublea Life It’s a stretch, but doctors who work bench to bedside say they wouldn’t do it any other way. FEATURES 14 On Human Terms 24 The Evolutionary War A small—some say too small—group of Efforts to undermine evolution education have physician-scientists believes the best science evolved into a 21st-century marketing cam- requires patient contact. paign that relies on legal acumen, manipulation By Marlene Cimons of scientific literature and grassroots tactics. 20 Engineering the Cell By Trisha Gura Adam Arkin sees the cell as a mechanical system. He hopes to transform molecular 28 Call of the Wild biology into a kind of cellular engineering Could quirky, new animal models help scien- and in the process, learn how to move cells tists learn how to regenerate human limbs or from sickness to health. avert the debilitating effects of a stroke? By M. Mitchell Waldrop By Kathryn Brown 24 In front of a crowd of 1,500, Ohio’s Board of Education heard testimony on whether students should learn about intelligent design in science class. DEPARTMENTS 2 NOTA BENE 33 PERSPECTIVE ulletin Intelligent Design Is a Cop-Out 4 LETTERS September 2002 || Volume 15 Number 3 NEWS AND NOTES HHMI TRUSTEES PRESIDENT’S LETTER 5 JAMES A. BAKER, III, ESQ. 34 Senior Partner, Baker & Botts A Creative Influence In from the Fields ALEXANDER G. BEARN, M.D. Executive Officer, American Philosophical Society 35 Lost on the Tip of the Tongue Adjunct Professor, The Rockefeller University UP FRONT Professor Emeritus of Medicine, Cornell University Medical College 36 Biology by Numbers FRANK WILLIAM GAY 6 Follow the Songbird Former President and Chief Executive Officer, SUMMA Corporation JAMES H. -
NSABB June-July 2005 Meeting Agenda
First Meeting of the National Science Advisory Board for Biosecurity June 30 – July 1, 2005 Hyatt Regency Bethesda 7400 Wisconsin Ave. Bethesda, Maryland, 20814 USA Hotel Phone: 301-657-1234 Agenda Webcast: To watch the live webcast of the meeting, click here. The webcast can only be viewed when the meeting is in session at 8:00am-6:00pm on June 30 and at 8:00am-1:30pm on July 1 Eastern Time. You will need RealOne Player to view the webcast. If you do not already have RealOne Player on your computer, download here. Presentation slides: To access the following PowerPoint presentations, click on the presentation titles below. June 30, 2005 Opening Remarks and Swearing in Ceremony Elias Zerhouni, M.D. Director of the National Institutes of Health (NIH) Chair's Remarks and Agenda Overview Dennis L. Kasper, M.D. NSABB Chair Harvard Medical School Introduction of NSABB Members NSABB Structure and Operations Thomas Holohan, M.D. NSABB Executive Director, NIH Office of Biotechnology Activities Break Perspectives on Biosecurity in the Life Sciences NSABB Voting Members Impetus for NSABB: Enhancing Biosecurity on the Life Sciences Rajeev Venkayya, M.D. Special Assistant to the President, Senior Director for Biological and Chemical Defense White House Homeland Security Council Perspectives on Biosecurity in the Life Sciences NSABB Ex Officio Members Lunch Session I- The Development of Criteria for Identifying Dual Use Research and Research Results Introduction: Issues of Relevance to Criteria Development Arturo Casadevall, M.D., Ph.D. Professor of Medicine and of Microbiology & Immunology and Chief of Infectious Diseases Albert Einstein College of Medicine National Research Council Perspective: Experiments of Concern Ron Atlas, Ph.D. -
And Should Not, Change Toxic Tort Causation Doctrine
THE MORE WE KNOW, THE LESS INTELLIGENT WE ARE? - HOW GENOMIC INFORMATION SHOULD, AND SHOULD NOT, CHANGE TOXIC TORT CAUSATION DOCTRINE Steve C. Gold* Advances in genomic science are rapidly increasing our understanding of dis- ease and toxicity at the most fundamental biological level. Some say this heralds a new era of certainty in linking toxic substances to human illness in the courtroom. Others are skeptical. In this Article I argue that the new sciences of molecular epidemiology and toxicogenomics will evince both remarkable explanatory power and intractable complexity. Therefore, even when these sciences are brought to bear, toxic tort claims will continue to present their familiar jurisprudential problems. Nevertheless, as genomic information is used in toxic tort cases, the sci- entific developments will offer courts an opportunity to correct mistakes of the past. Courts will miss those opportunities, however, if they simply transfer attitudesfrom classical epidemiology and toxicology to molecular and genomic knowledge. Using the possible link between trichloroethyleneand a type of kidney cancer as an exam- ple, I describe several causation issues where courts can, if they choose, improve doctrine by properly understanding and utilizing genomic information. L Introduction ............................................... 370 II. Causation in Toxic Torts Before Genomics ................... 371 A. The Problem .......................................... 371 B. Classical Sources of Causation Evidence ................ 372 C. The Courts Embrace Epidemiology - Perhaps Too Tightly ................................................ 374 D. Evidence Meets Substance: Keepers of the Gate ......... 379 E. The Opposing Tendency ................................ 382 III. Genomics, Toxicogenomics, and Molecular Epidemiology: The M ore We Know ........................................ 383 A. Genetic Variability and "Background" Risk .............. 384 B. Genetic Variability and Exposure Risk ................... 389 C. -
Dean, School of Science
Dean, School of Science School of Science faculty members seek to answer fundamental questions about nature ranging in scope from the microscopic—where a neuroscientist might isolate the electrical activity of a single neuron—to the telescopic—where an astrophysicist might scan hundreds of thousands of stars to find Earth-like planets in their orbits. Their research will bring us a better understanding of the nature of our universe, and will help us address major challenges to improving and sustaining our quality of life, such as developing viable resources of renewable energy or unravelling the complex mechanics of Alzheimer’s and other diseases of the aging brain. These profound and important questions often require collaborations across departments or schools. At the School of Science, such boundaries do not prevent people from working together; our faculty cross such boundaries as easily as they walk across the invisible boundary between one building and another in our campus’s interconnected buildings. Collaborations across School and department lines are facilitated by affiliations with MIT’s numerous laboratories, centers, and institutes, such as the Institute for Data, Systems, and Society, as well as through participation in interdisciplinary initiatives, such as the Aging Brain Initiative or the Transiting Exoplanet Survey Satellite. Our faculty’s commitment to teaching and mentorship, like their research, is not constrained by lines between schools or departments. School of Science faculty teach General Institute Requirement subjects in biology, chemistry, mathematics, and physics that provide the conceptual foundation of every undergraduate student’s education at MIT. The School faculty solidify cross-disciplinary connections through participation in graduate programs established in collaboration with School of Engineering, such as the programs in biophysics, microbiology, or molecular and cellular neuroscience. -
SCRIPPS DISCOVERS FALL 2010 Selective Inhibition of BMK1 Suppresses Tumor Growth
SC RIPPS DISC OVERS Accelerating Discoveries, Saving Lives A Newsletter for Philanthropists Published Quarterly by The Scripps Research Institute WINTER 2010 | VOL 7 | NO 1 California-Florida RESEARCH UPDATE Scripps Research Scientists Develop Molecular Test Providing a New Pathway for Identifying Obesity and Diabetes Drugs cientists at The Scripps Research Institute The Worm Institute for Research and Medicine have designed a new molecular test that at Scripps Research. Swill allow researchers to look for potential Janda and Amanda Garner, Ph.D., a research drugs targeting a human metabolic enzyme believed associate in his laboratory, described the new to stimulate the appetite and play a role in diabetes. approach—which may also prove useful for The new test, which the scientists call a simple investigating other enzymes involved in a assay, will allow researchers to look through variety of diseases—in an advance, online Early hundreds of thousands of compounds for those that Edition of the journal Angewandte Chemie on have potential to block the action of an enzyme September 15, 2010. known as ghrelin O-acyltransferase (GOAT). If Even though GOAT was only discovered drugs can be found that safely suppress the action recently, in 2008, scientists had speculated for of GOAT, they may help people who have clinical years that it had to exist. After all, its target (ghrelin, problems with appetite, obesity, and diabetes. or the “G” in the acronym GOAT) had been Professor Kim Janda “There hasn’t been a simple screen until now,” known for more than a decade. says Kim D. Janda, Ph.D., a professor in the Ghrelin, a small peptide hormone that is Departments of Chemistry and Immunology mainly produced in the stomach, signals hunger, and Microbial Science, member of The Skaggs typically before meals. -
Applied Biosystems 7500 Real-Time PCR System and Applied Biosystems 7500 Fast Real-Time PCR System a Real Fast and Real Versatile Approach to Real-Time PCR
58374r1_AB04499 12/15/04 10:50 PM Page 1 Specification Sheet Real-Time PCR Systems Applied Biosystems 7500 Real-Time PCR System and Applied Biosystems 7500 Fast Real-Time PCR System A Real Fast and Real Versatile Approach to Real-Time PCR • The 7500 Fast Real-Time PCR System enables standard 96-well format high speed thermal cycling, significantly reducing your run time for quantitative real-time PCR applications, deliv- ering results in about 35 minutes Applied Biosystems 7500 Real-Time PCR System Applied Biosystems 7500 Fast Real-Time PCR System • The 7500 Real-Time PCR System is a versatile, leading-edge platform providing enhanced performance •Small instrument footprint permits Fast Thermal Cycling capabilities and an upgrade path easy placement in any laboratory, The 7500 System is available in two to high-speed thermal cycling even those with limited space configurations; the 7500 Fast System configuration with a high-speed, 96- •Five-color detection system provides Introduction well format thermal cycling block the flexibility to perform a variety The Applied Biosystems 7500 and capable of quantitative real-time PCR of applications including gene 7500 Fast Real-Time PCR Systems are runs in about 35 minutes, and the expression analysis, SNP genotyp- integrated, versatile platforms for the standard configuration with a 96-well ing and plus/minus assays that detection and quantification of nucleic format thermal cycling block with utilize internal positive controls acid sequences. Real-time PCR com- run times of under 2 hours. A service bines thermal cycling, fluorescence •Advanced optical configuration engineer installed Fast Upgrade Kit detection, and application-specific supports a broader range of fluo- is available for the 7500 System to software to measure the cycle-by-cycle rophores, including FAM™/SYBR® upgrade it to the Fast configuration. -
APPLERA CORPORATION Annual Report
312849_Applera_REVISED0914.qxd 9/17/01 6:42 PM Page 2 2001APPLERA CORPORATION Annual Report APPLIED BIOSYSTEMS CELERA GENOMICS 312849_Applera_REVISED0914.qxd 9/17/01 6:42 PM Page 3 Table of CONTENTS Letter to Stockholders Applera Corporation 3 Applied Biosystems Group 5 Celera Genomics Group 7 Celera Diagnostics 8 Financial Review 10 Directors and Officers 109 Stockholder Information 110 APPLERA CORPORATION Mission: To provide the world’s leading technology and information solutions that help life scientists understand and use the power of biology. Business Groups: Applied Biosystems and Celera Genomics Headquarters: Norwalk, Connecticut APPLIED BIOSYSTEMS GROUP Profile: A leading provider of technology solutions for life science research and related applications, with customers in over 100 countries. Headquarters: Foster City, California New York Stock Exchange Symbol: ABI CELERA GENOMICS GROUP Profile: A biopharmaceutical business and leading provider of genomic and related medical information, enabling therapeutics discovery using proprietary scientific capabilities for the group’s internal efforts and in partnership with pharmaceutical and biotechnology companies. Headquarters: Rockville, Maryland New York Stock Exchange Symbol: CRA CELERA DIAGNOSTICS Profile: A joint venture between Applied Biosystems and Celera Genomics that is leveraging capabilities from both businesses to develop new molecular and protein diagnostics. Headquarters: Alameda, California 312849_Applera_REVISED0914.qxd 9/17/01 6:42 PM Page 4 To our stockholders: Applera Corporation continues to be a leader This should allow us to more effectively in the life science revolution – a revolution many anticipate customers’ needs and bring products believe could define this new century. We enter to market in a more timely manner, while fiscal year 2002 at the threshold of major maintaining the technological innovation that advances in the field of disease diagnosis and has made us a premier provider of life science therapeutics discoveries, made possible in part by tools. -
EMBC Annual Report 2007
EMBO | EMBC annual report 2007 EUROPEAN MOLECULAR BIOLOGY ORGANIZATION | EUROPEAN MOLECULAR BIOLOGY CONFERENCE EMBO | EMBC table of contents introduction preface by Hermann Bujard, EMBO 4 preface by Tim Hunt and Christiane Nüsslein-Volhard, EMBO Council 6 preface by Marja Makarow and Isabella Beretta, EMBC 7 past & present timeline 10 brief history 11 EMBO | EMBC | EMBL aims 12 EMBO actions 2007 15 EMBC actions 2007 17 EMBO & EMBC programmes and activities fellowship programme 20 courses & workshops programme 21 young investigator programme 22 installation grants 23 science & society programme 24 electronic information programme 25 EMBO activities The EMBO Journal 28 EMBO reports 29 Molecular Systems Biology 30 journal subject categories 31 national science reviews 32 women in science 33 gold medal 34 award for communication in the life sciences 35 plenary lectures 36 communications 37 European Life Sciences Forum (ELSF) 38 ➔ 2 table of contents appendix EMBC delegates and advisers 42 EMBC scale of contributions 49 EMBO council members 2007 50 EMBO committee members & auditors 2007 51 EMBO council members 2008 52 EMBO committee members & auditors 2008 53 EMBO members elected in 2007 54 advisory editorial boards & senior editors 2007 64 long-term fellowship awards 2007 66 long-term fellowships: statistics 82 long-term fellowships 2007: geographical distribution 84 short-term fellowship awards 2007 86 short-term fellowships: statistics 104 short-term fellowships 2007: geographical distribution 106 young investigators 2007 108 installation -
2019 Annual Report
BECKMAN CENTER 279 Campus Drive West Stanford, CA 94305 650.723.8423 Stanford University | Beckman Center 2019 Annual Report Annual 2019 | Beckman Center University Stanford beckman.stanford.edu 2019 ANNUAL REPORT ARNOLD AND MABEL BECKMAN CENTER FOR MOLECULAR AND GENETIC MEDICINE 30 Years of Innovation, Discovery, and Leadership in the Life Sciences CREDITS: Cover Design: Neil Murphy, Ghostdog Design Graphic Design: Jack Lem, AlphaGraphics Mountain View Photography: Justin Lewis Beckman Center Director Photo: Christine Baker, Lotus Pod Designs MESSAGE FROM THE DIRECTOR Dear Friends and Trustees, It has been 30 years since the Beckman Center for Molecular and Genetic Medicine at Stanford University School of Medicine opened its doors in 1989. The number of translational scientific discoveries and technological innovations derived from the center’s research labs over the course of the past three decades has been remarkable. Equally remarkable have been the number of scientific awards and honors, including Nobel prizes, received by Beckman faculty and the number of young scientists mentored by Beckman faculty who have gone on to prominent positions in academia, bio-technology and related fields. This year we include several featured articles on these accomplishments. In the field of translational medicine, these discoveries range from the causes of skin, bladder and other cancers, to the identification of human stem cells, from the design of new antifungals and antibiotics to the molecular underpinnings of autism, and from opioids for pain -
Michael S. Brown, MD
DISTINGUISHED PHYSICIANS AND Michael S. Brown, M.D. Sir Richard Roberts, Ph.D. Winner, 1985 Nobel Prize in Physiology or Medicine Winner, 1993 Nobel Prize in Physiology or Medicine MEDICAL SCIENTISTS MENTORING Winner, 1988 Presidential National Medal of Science A globally prominent biochemist and molecular biologist, DELEGATES HAVE INCLUDED... Dr. Brown received the world’s most prestigious medical Dr. Roberts was awarded the Nobel Prize for his prize for his work describing the regulation of the groundbreaking contribution to discovering RNA splicing. cholesterol metabolism. His work laid the foundation for Dr. Roberts is dedicating his future research to GMO crops the class of drugs now called statins taken daily by more than 20 million and food sources, and demonstrating the effect they have on humanity. — GRANDg MASTERS — people worldwide. Ferid Murad, M.D., Ph.D. Mario Capecchi, Ph.D. Boris D. Lushniak, M.D., M.P.H Winner, 1998 Nobel Prize in Physiology or Medicine Academy Science Director The Surgeon General of the United States (acting, 2013-2014) Winner, 2007 Nobel Prize in Physiology or Medicine A world-renowned pioneer in biochemistry, Dr. Murad’s Winner, 2001 National Medal of Science Rear Admiral Lushniak, M.D., M.P.H., was the United award-winning research demonstrated that nitroglycerin Winner, 2001 Lasker Award States’ leading spokesperson on matters of public health, and related drugs help patients with heart conditions by Winner, 2003 Wolf Prize in Medicine overseeing the operations of the U.S. Public Health Service releasing nitric oxide into the body, thus relaxing smooth Mario Capecchi, Ph.D., a biophysicist, is a Distinguished Commissioned Corps, which consists of approximately muscles by elevating intracellular cyclic GMP, leading to vasodilation and Professor of Human Genetics at the University of Utah School of Medicine. -
Precision Medicine Initiative: Building a Large US Research Cohort
Precision Medicine Initiative: Building a Large U.S. Research Cohort February 11-12, 2015 PARTICIPANT LIST Goncalo Abecasis, D. Phil. Philip Bourne, Ph.D. Professor of Biostatistics Associate Director for Data Science University of Michigan, Ann Arbor Office of the Director National Institutes of Health Christopher Austin, M.D. Director Murray Brilliant, Ph.D. National Center for Advancing Translational Sciences Director National Institutes of Health Center for Human Genetics Marshfield Clinic Research Foundation Vikram Bajaj, Ph.D. Chief Scientist Greg Burke, M.D., M.Sc. Google Life Sciences Professor and Director Wake Forest School of Medicine Dixie Baker, Ph.D. Wake Forest University Senior Partner Martin, Blanck and Associates Antonia Calafat, Ph.D. Chief Dana Boyd Barr, Ph.D. Organic Analytical Toxicology Branch Professor, Exposure Science and Environmental Health Centers for Disease Control and Prevention Rollins School of Public Health Emory University Robert Califf, M.D. Vice Chancellor for Clinical and Translational Research Jonathan Bingham, M.B.A. Duke University Medical Center Product Manager, Genomics Google, Inc. Rex Chisholm, Ph.D. Adam and Richard T. Lind Professor of Medical Eric Boerwinkle, Ph.D. Genetics Professor and Chair Vice Dean for Scientific Affairs and Graduate Studies Human Genetics Center Associate Vice President for Research University of Texas Health Science Center Northwestern University Associate Director Human Genome Sequencing Center Rick Cnossen, M.S. Baylor College of Medicine Director Global Healthcare Solutions Erwin Bottinger, M.D. HIMSS Board of Directors Professor PCHA/Continua Health Alliance Board of Directors The Charles Bronfman Institute for Personalized Intel Corporation Medicine Icahn School of Medicine at Mount Sinai - 1 - Francis Collins, M.D., Ph.D.